Title
Category
Credits
Event date
Cost
Monkeypox Explained: Symptoms, Transmissibility and Prevention
  • Infectious diseases
  • 0.50 ACPE - Pharmacists
  • 0.50 ACPE - Pharmacy Technicians
  • 0.50 AMA - Physicians
  • 0.50 ANCC - Nurses
  • 0.50 APA - Psychologists
  • 0.50 Attendance - General Attendance
  • 0.50 ASWB - Social Workers
$0.00
This activity will provide participants with the latest science on monkeypox, describing the spectrum of associated symptoms and signs, virulence, and common routes of transmission. Discussion will also focus on the factors driving this outbreak, approaches to prevention and management, and an overview of the impact of this disease globally and in comparison with the current COVID-19 public health emergency.
Diabesity: A Call for Urgent Action
  • Disease management
  • Wellness
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity will highlight new updates in our understanding of how diabesity develops and describe the negative physiologic effects of this disease on multiple body systems, notably the cardiovascular and renal systems. Optimal treatments for diabesity will be identified, along with an overview of the health burden of diabesity related to long-term complications and reduced function, quality of life and life expectancy. 
Understanding How Eating Disorders Impact Those in the Child Welfare System
  • Pediatrics
  • 1.50 ACPE - Pharmacists
  • 1.50 ACPE - Pharmacy Technicians
  • 1.50 AMA - Physicians
  • 1.50 ANCC - Nurses
  • 1.50 APA - Psychologists
  • 1.50 Attendance - General Attendance
  • 1.50 ASWB - Social Workers
$0.00
This activity will discuss the connection between childhood trauma and eating disorders and how to better assess the risk of young people within the child welfare system developing eating disorders. It also will provide HCPs with guidance regarding improved recognition of the underlying conditions and experiences that must be addressed to successfully treat individuals struggling with disordered eating.
CRISPR-Based Therapies for Genetic Blood Disorders
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
Join this session to explore updates in genetic therapy for two prevalent hemaglobinopathies: sickle cell disease and beta thalassemia.
Exploring Opioid Crisis Dynamics: New Perspectives and Strategies
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will focus on enhancing our understanding of the current opioid crisis and will explore new angles and address current concerns, including the use of over-the-counter intranasal naloxone, the evolving landscape of opioids with a focus on fentanyl, the intersection between suicide and opioid overdoses, the significance of the new 988 helpline in the crisis, and the viability of home-based detox startups. Strategies to effectively address the ongoing challenges of the opioid crisis will be discussed.
Insights into Addressing the Risks of Cardiovascular Health in Women
  • Women's health
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will provide an overview of cardiovascular risk factors specific to women and explore the latest strategies and tools for assessing and mitigating these risks and improving overall cardiovascular care.
Perimenopause: Managing Common Conundrums
  • Women's health
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will address updates in evidence-based PM screening strategies, diagnosis, and treatment approaches. It will review the unique challenges faced by women in the perimenopausal stage and discuss the range of physical, emotional, and cognitive symptoms commonly experienced. Participants will be empowered to participate in shared decision-making through improved communication with patients experiencing PM.
Evidence-based Approach to Headache Management in Primary Care
  • Disease management
  • Wellness
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 Attendance - General Attendance
$0.00
The activity will examine traditional therapies for migraine, both acute and preventive, and introduce cutting-edge anti-calcitonin gene-related peptide (CGRP) targeted therapies. It will compare the efficacy and application of these treatments, enabling informed decision-making in clinical practice.
The Battle Against Alzheimer’s Disease: New Advancements, Treatments and Hope
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity will discuss the latest advances in AD diagnosis and management, including biomarkers, imaging techniques and cognitive assessments. Emerging pharmacological therapies that target the underlying disease and novel approaches to optimizing patient care will be highlighted.
Schizophrenic Patients on Long-term Oral/Topical Antipsychotic Treatment Without a Trial of Atypical Long-acting Injectable Therapy: A Tenncare Initiative
  • Behavioral health
  • 0.50 ACPE - Pharmacists
  • 0.50 ACPE - Pharmacy Technicians
  • 0.50 AMA - Physicians
  • 0.50 ANCC - Nurses
  • 0.50 Attendance - General Attendance
$0.00
This E-newsletter will provide an overview of the program, including details regarding the benefits of LAI atypical antipsychotics and other available agents, a brief review of schizophrenia and potential clinical steps. Additional information regarding the retrospective drug utilization review process and the rationale for brand drug preference will also be highlighted.

Pages